Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Preclinical Alzheimer's disease (AD) is a relatively recent concept describing an entity characterized by the presence of a pathophysiological biomarker signature characteristic for AD in the absence of specific clinical symptoms. There is rising interest in the scientific community to define such an early target population mainly because of failures of all recent clinical trials despite evidence of biological effects on brain amyloidosis for some compounds. A conceptual framework has recently been proposed for this preclinical phase of AD. However, few data exist on this silent stage of AD. We performed a systematic review to investigate how the concept is defined across studies. The review highlights the substantial heterogeneity concerning the three main determinants of preclinical AD: “normal cognition,” “cognitive decline,” and “AD pathophysiological signature.” We emphasize the need for a harmonized nomenclature of the preclinical AD concept and standardized population‐based and case‐control studies using unified operationalized criteria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“Crosssectional studies have been performed in these asymptomatic carriers to analyze the biomarker differences over time and to hypothesize their evolution [21].”
BackgroundAdvancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationHyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · cited 2×
“Of note for further studies, the recommendation to consider preclinical AD only in case of Aß and tau positive markers points to the need to use either Aß and tau combinations of CSF biomarkers (12/50 studies with biomarkers in this review) or both Aß and tau PET tracers (0 article in this review) [20].”
BackgroundThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“possible efficacy of disease modifying drugs in the early clinical stage of AD [24,27].”
BackgroundJessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.001 · Cited by 3,014 · cited 4×
“Studies conducted on the preclinical AD concept could be harmonized by 1) using tests to assess attention and psychomotor speed (such as the Digit Span Forward and DSST), executive functions (e.g., verbal fluencies, TMT), questionnaires to assess SCD, episodic memory (FCSRT), and global cognitive functioning (MMSE and…”
BackgroundInfluentialSelf-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“After the problematic experience with the vastly heterogeneous application of prodromal “MCI” concepts to research studies and drug development programs in AD [23] and failures of recent large-scale trials aiming at slowing down progression of the disease in patients with mildto-moderate AD [24,25], great interest has…”
BackgroundPreclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925 · cited 4×
“The recent release of consensual criteria should facilitate the harmonization and the quality of epidemiological and interventional research on preclinical AD [1].”
BackgroundInfluentialSelf-citationPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 2×
“possible efficacy of disease modifying drugs in the early clinical stage of AD [24,27].”
BackgroundThe Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective
Mahmood, S. S., Levy, D., Vasan, R. S., & Wang, T. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61752-3 · Cited by 1,622 · cited 1×
“This choice was mainly made for one reason: to derive robust criteria for a disease or its risk factors you need an epidemiological study with a large number of participants and a long duration of follow-up, much like what the Framingham cohort brought to the cardiovascular field [58,59].”
BackgroundUse of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
The Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline
Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., Weiner, M., & Aisen, P. S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.803 · Cited by 860
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
Prodromal Alzheimer's disease: successive emergence of the clinical symptoms
Amieva, H., Le Goff, M., Millet, X., Orgogozo, J. M., Pérès, K., Barberger‐Gateau, P., Jacqmin‐Gadda, H., & Dartigues, J. F. (2008) · Annals of Neurology · doi:10.1002/ana.21509 · Cited by 737
The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials
Sperling, R., Mormino, E., & Johnson, K. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.038 · Cited by 725
Snowdon, D. A. (1996) · JAMA · doi:10.1001/jama.1996.03530310034029 · Cited by 696 · cited 1×
“…Postmortem neuropathologic evaluations in a subsample https://www.alz. washington.edu[68] Yes No No No No Yes Postmortem neuropathologic evaluations Snowdon et al. (1996) [69] Yes Yes Yes No Optional Yes None Alcolea et al. (2015) [70] Yes Yes No No No Yes No Vos et al. (2013) [71] Yes No No No…”
BackgroundBerg, L., McKeel, D. W., Miller, J. P., Storandt, M., Rubin, E. H., Morris, J. C., Baty, J., Coats, M., Norton, J., Goate, A. M., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.326 · Cited by 657
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70194-7 · Cited by 564 · cited 1×
“…Postmortem neuropathologic evaluations Snowdon et al. (1996) [69] Yes Yes Yes No Optional Yes None Alcolea et al. (2015) [70] Yes Yes No No No Yes No Vos et al. (2013) [71] Yes No No No No Yes No Sager et al. (2005) [72]; La Rue et al. (2008) [73] Initiative, the Australian Imaging, the…”
BackgroundRohrer, J. D., Nicholas, J. M., Cash, D. M., van Swieten, J., Dopper, E., Jiskoot, L., van Minkelen, R., Rombouts, S. A., Cardoso, M. J., Clegg, S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70324-2 · Cited by 538
Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476
Subjective cognitive complaints and amyloid burden in cognitively normal older individuals
Amariglio, R. E., Becker, J. A., Carmasin, J., Wadsworth, L. P., Lorius, N., Sullivan, C., Maye, J. E., Gidicsin, C., Pepin, L. C., Sperling, R. A., et al. (2012) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2012.08.011 · Cited by 472 · cited 1×
“MMSE scores when used as cutoff points between normality and impairment varied from 26 [13,14] to 28 [15].”
Methoddel Campo, M., Mollenhauer, B., Bertolotto, A., Engelborghs, S., Hampel, H., Simonsen, A. H., Kapaki, E., Kruse, N., Le Bastard, N., Lehmann, S., et al. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.46 · Cited by 343 · cited 1×
“In conclusion, even if total standardization of different markers of cognition and AD signature cannot be achieved, the community should agree on the use of some general tools to provide robust knowledge on the preclinical AD concept, for instance, DSST, CDR, FCSRT for the neurocognitive evaluation, CSF biomarker eval…”
MethodSelf-citationMormino, E. C., Betensky, R. A., Hedden, T., Schultz, A. P., Amariglio, R. E., Rentz, D. M., Johnson, K. A., & Sperling, R. A. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2031 · Cited by 328
Delaère, P., Duyckaerts, C., Masters, C., Beyreuther, K., Piette, F., & Hauw, J.-J. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90391-l · Cited by 186
Indicators of amyloid burden in a population-based study of cognitively normal elderly
Mielke, M. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Roberts, R. O., Geda, Y. E., Swenson-Dravis, D. M., Boeve, B. F., Senjem, M. L., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e2696 · Cited by 163
Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease
Alcolea, D., Martínez-Lage, P., Sánchez-Juan, P., Olazarán, J., Antúnez, C., Izagirre, A., Ecay-Torres, M., Estanga, A., Clerigué, M., Guisasola, M. C., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001859 · Cited by 163 · cited 2×
“…No No No No Yes Postmortem neuropathologic evaluations Snowdon et al. (1996) [69] Yes Yes Yes No Optional Yes None Alcolea et al. (2015) [70] Yes Yes No No No Yes No Vos et al. (2013) [71] Yes No No No No Yes No Sager et al. (2005) [72]; La Rue et al. (2008)…”
BackgroundInfluentialPreclinical AD predicts decline in memory and executive functions in subjective complaints
van Harten, A. C., Smits, L. L., Teunissen, C. E., Visser, P. J., Koene, T., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a8418b · Cited by 143
Preclinical AD Workgroup staging: Pathological correlates and potential challenges
Jicha, G. A., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Riley, K. P., Cooper, G. E., Stiles, N., Mendiondo, M. S., Smith, C. D., Van Eldik, L. J., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.018 · Cited by 71 · cited 2×
“5) NIA-AA PC AD criteria [7] or [19] 8 (36.”
Background
Cited by
The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders
Pawelec, P., Ziemka-Nalecz, M., Sypecka, J., & Zalewska, T. (2020) · Cells · doi:10.3390/cells9102277 · Cited by 269
Dubois, B., Epelbaum, S., Nyasse, F., Bakardjian, H., Gagliardi, G., Uspenskaya, O., Houot, M., Lista, S., Cacciamani, F., Potier, M.-C., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30029-2 · Cited by 237
Self-citationOxidant/Antioxidant Imbalance in Alzheimer’s Disease: Therapeutic and Diagnostic Prospects
Wojsiat, J., Zoltowska, K. M., Laskowska-Kaszub, K., & Wojda, U. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6435861 · Cited by 221
Beltrami, D., Gagliardi, G., Rossini Favretti, R., Ghidoni, E., Tamburini, F., & Calzà, L. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00369 · Cited by 175
Self-citationBiomarkers for Alzheimer’s Disease
Guzman-Martinez, L., Maccioni, R. B., Farías, G. A., Fuentes, P., & Navarrete, L. P. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190517121140 · Cited by 87
Metadata
- Authors
- Epelbaum, S., Genthon, R., Cavedo, E., Habert, M. O., Lamari, F., Gagliardi, G., Lista, S., Teichmann, M., Bakardjian, H., Hampel, H., & Dubois, B.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2017-02-07
- Volume
- 13
- Issue
- 4
- Pages
- 454-467
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2586242021
- Cited by
- 77
- References
- 28
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.